Literature DB >> 24599525

What is the role of chemotherapy in the treatment of melanoma?

Ahmed I Megahed1, Henry B Koon.   

Abstract

The approval of ipilimumab and inhibitors of the BRAF pathway for the treatment of melanoma has provided multiple therapeutic options for patients. Although these new agents improve survival compared with chemotherapy alone, the majority of patients will progress and will receive chemotherapy at some point in the course of their disease. Whether the clinical efficacy of chemotherapy can be improved by targeting resistance mechanisms is an area of active investigation. In addition, chemotherapy may be of use modulating the efficacy of the newer agents.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24599525     DOI： 10.1007/s11864-014-0277-5

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN： 1534-6277


  76 in total

1.  Improved survival with MEK inhibition in BRAF-mutated melanoma.

Authors:  Keith T Flaherty; Caroline Robert; Peter Hersey; Paul Nathan; Claus Garbe; Mohammed Milhem; Lev V Demidov; Jessica C Hassel; Piotr Rutkowski; Peter Mohr; Reinhard Dummer; Uwe Trefzer; James M G Larkin; Jochen Utikal; Brigitte Dreno; Marta Nyakas; Mark R Middleton; Jürgen C Becker; Michelle Casey; Laurie J Sherman; Frank S Wu; Daniele Ouellet; Anne-Marie Martin; Kiran Patel; Dirk Schadendorf
Journal:  N Engl J Med       Date:  2012-06-04       Impact factor: 91.245

2.  Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel.

Authors:  Nuhad K Ibrahim; Neil Desai; Sewa Legha; Patrick Soon-Shiong; Richard L Theriault; Edgardo Rivera; Bita Esmaeli; Sigrid E Ring; Agop Bedikian; Gabriel N Hortobagyi; Julie A Ellerhorst
Journal:  Clin Cancer Res       Date:  2002-05       Impact factor: 12.531

3.  Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group.

Authors:  Ulrich Keilholz; Cornelis J A Punt; Martin Gore; Wim Kruit; Poulam Patel; Danielle Lienard; Jose Thomas; Thomas M Proebstle; Alexander Schmittel; Dirk Schadendorf; Thierry Velu; Sylvie Negrier; Ulrich Kleeberg; Frederic Lehman; Stefan Suciu; Alexander M M Eggermont
Journal:  J Clin Oncol       Date:  2005-09-20       Impact factor: 44.544

4.  Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion.

Authors:  Daniel J Powell; Mark E Dudley; Katherine A Hogan; John R Wunderlich; Steven A Rosenberg
Journal:  J Immunol       Date:  2006-11-01       Impact factor: 5.422

5.  A multicenter trial of interleukin-2 and low-dose cyclophosphamide in highly chemotherapy-resistant malignancies.

Authors:  A Lindemann; K Hoeffken; R E Schmidt; V Diehl; O Kloke; H Gamm; J Hayungs; W Oster; M Boehm; C R Franks
Journal:  Cancer Treat Rev       Date:  1989-06       Impact factor: 12.111

Review 6.  Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go?

Authors:  Pawel Muranski; Andrea Boni; Claudia Wrzesinski; Deborah E Citrin; Steven A Rosenberg; Richard Childs; Nicholas P Restifo
Journal:  Nat Clin Pract Oncol       Date:  2006-12

7.  Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b.

Authors:  S A Rosenberg; J C Yang; D J Schwartzentruber; P Hwu; F M Marincola; S L Topalian; C A Seipp; J H Einhorn; D E White; S M Steinberg
Journal:  J Clin Oncol       Date:  1999-03       Impact factor: 44.544

8.  Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma.

Authors:  Malcolm Ranson; Peter Hersey; Damien Thompson; Jane Beith; Grant A McArthur; Andrew Haydon; Ian D Davis; Richard F Kefford; Peter Mortimer; Peter A Harris; Sofia Baka; Augustus Seebaran; Ami Sabharwal; Amanda J Watson; Geoffrey P Margison; Mark R Middleton
Journal:  J Clin Oncol       Date:  2007-06-20       Impact factor: 44.544

9.  Evaluation of the exposure equivalence of oral versus intravenous temozolomide.

Authors:  Blanca D Diez; Paul Statkevich; Yali Zhu; Malaz A Abutarif; Fengjuan Xuan; Bhavna Kantesaria; David Cutler; Marc Cantillon; Max Schwarz; Maria Guadalupe Pallotta; Fabio H Ottaviano
Journal:  Cancer Chemother Pharmacol       Date:  2009-07-30       Impact factor: 3.333

10.  Human CD4+CD25+ regulatory T cells are sensitive to low dose cyclophosphamide: implications for the immune response.

Authors:  Daniel Heylmann; Martina Bauer; Huong Becker; Stefaan van Gool; Nicole Bacher; Kerstin Steinbrink; Bernd Kaina
Journal:  PLoS One       Date:  2013-12-23       Impact factor: 3.240
View more
  9 in total

1.  Climacostol reduces tumour progression in a mouse model of melanoma via the p53-dependent intrinsic apoptotic programme.

Authors:  Cristiana Perrotta; Federico Buonanno; Silvia Zecchini; Alessio Giavazzi; Francesca Proietti Serafini; Elisabetta Catalani; Laura Guerra; Maria Cristina Belardinelli; Simona Picchietti; Anna Maria Fausto; Simone Giorgi; Enrico Marcantoni; Emilio Clementi; Claudio Ortenzi; Davide Cervia
Journal:  Sci Rep       Date:  2016-06-07       Impact factor: 4.379

2.  Endoplasmic reticulum stress-induced autophagy determines the susceptibility of melanoma cells to dabrafenib.

Authors:  Chao Ji; Ziping Zhang; Lihong Chen; Kunli Zhou; Dongjun Li; Ping Wang; Shuying Huang; Ting Gong; Bo Cheng
Journal:  Drug Des Devel Ther       Date:  2016-08-04       Impact factor: 4.162

3.  Essential role for acid sphingomyelinase-inhibited autophagy in melanoma response to cisplatin.

Authors:  Davide Cervia; Emma Assi; Clara De Palma; Matteo Giovarelli; Laura Bizzozero; Sarah Pambianco; Ilaria Di Renzo; Silvia Zecchini; Claudia Moscheni; Chiara Vantaggiato; Patrizia Procacci; Emilio Clementi; Cristiana Perrotta
Journal:  Oncotarget       Date:  2016-05-03

4.  Senescence-associated secretory factors induced by cisplatin in melanoma cells promote non-senescent melanoma cell growth through activation of the ERK1/2-RSK1 pathway.

Authors:  Xuerong Sun; Benyan Shi; Huiling Zheng; Ling Min; Jie Yang; Xiaoyi Li; Xiaoxin Liao; Weixing Huang; Mingmeng Zhang; Shun Xu; Zhe Zhu; Hongjing Cui; Xinguang Liu
Journal:  Cell Death Dis       Date:  2018-02-15       Impact factor: 8.469

Review 5.  Photodynamic Therapy for Metastatic Melanoma Treatment: A Review.

Authors:  Channay Naidoo; Cherie Ann Kruger; Heidi Abrahamse
Journal:  Technol Cancer Res Treat       Date:  2018-01-01

6.  Application of the Transcriptional Disease Signature (TDSs) to Screen Melanoma-Effective Compounds in a Small Fish Model.

Authors:  Yuan Lu; William Boswell; Mikki Boswell; Barbara Klotz; Susanne Kneitz; Janine Regneri; Markita Savage; Cristina Mendoza; John Postlethwait; Wesley C Warren; Manfred Schartl; Ronald B Walter
Journal:  Sci Rep       Date:  2019-01-24       Impact factor: 4.379

7.  p38 MAPK activation through B7-H3-mediated DUSP10 repression promotes chemoresistance.

Authors:  Karine Flem-Karlsen; Christina Tekle; Tove Øyjord; Vivi A Flørenes; Gunhild M Mælandsmo; Øystein Fodstad; Caroline E Nunes-Xavier
Journal:  Sci Rep       Date:  2019-04-09       Impact factor: 4.379

8.  Potent USP10/13 antagonist spautin-1 suppresses melanoma growth via ROS-mediated DNA damage and exhibits synergy with cisplatin.

Authors:  Jia Guo; JiangLing Zhang; Long Liang; Nian Liu; Min Qi; Shuang Zhao; Juan Su; Jing Liu; Cong Peng; Xiang Chen; Hong Liu
Journal:  J Cell Mol Med       Date:  2020-03-04       Impact factor: 5.310

9.  Anticancer Activity of Amantadine and Evaluation of Its Interactions with Selected Cytostatics in Relation to Human Melanoma Cells.

Authors:  Danuta Krasowska; Agnieszka Gerkowicz; Paula Wróblewska-Łuczka; Aneta Grabarska; Katarzyna Załuska-Ogryzek; Dorota Krasowska; Jarogniew J Łuszczki
Journal:  Int J Mol Sci       Date:  2022-07-11       Impact factor: 6.208
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.